What Mass General Brigham Research Does

Mass General Brigham Research is the central research engine for one of the United States' premier academic medical systems. Founded in 2015, it unifies the vast research activities across flagship institutions like Massachusetts General Hospital and Brigham and Women's Hospital. With a workforce of 5,000-10,000, its mission is to conduct groundbreaking biomedical, clinical, and health services research that translates scientific discovery into advanced patient care. The organization manages thousands of studies, from basic science in labs to large-scale clinical trials, leveraging an unparalleled patient population and deep clinical data. Its work is fundamental to developing new treatments, understanding disease mechanisms, and improving healthcare delivery.

Why AI Matters at This Scale

For a research entity of this size and complexity, AI is not a luxury but a necessity to maintain competitive advantage and scientific impact. The sheer volume and variety of data—including genomic sequences, electronic health records, medical images, and published literature—far exceed human capacity to analyze comprehensively. AI and machine learning offer the only viable path to uncovering subtle patterns, generating novel hypotheses, and automating labor-intensive processes. At this scale, even marginal improvements in research efficiency or trial success rates can translate into hundreds of millions of dollars in saved costs and accelerated timelines for bringing life-saving therapies to patients. Furthermore, as a leader in an innovation hub like Boston, failing to adopt AI risks ceding ground to more agile biotech startups and peer institutions.

Concrete AI Opportunities with ROI Framing

1. Clinical Trial Acceleration: Manually screening EHRs for trial eligibility is slow and error-prone. An AI-powered patient-trial matching system can reduce recruitment timelines by 30-50%, cutting direct costs per trial by millions and enabling faster study completion. This directly increases research throughput and revenue from trial sponsors.

2. Predictive Biomarker Discovery: Analyzing multi-omics data with deep learning can identify novel biomarkers for diseases like cancer or Alzheimer's years earlier than traditional methods. This de-risks drug development pipelines, attracts pharmaceutical partnership deals, and positions the institute at the forefront of precision medicine.

3. Research Intelligence and Automation: Deploying Large Language Models (LLMs) to synthesize millions of research articles and automate grant-writing support can save each principal investigator 5-10 hours per week. Scaled across thousands of researchers, this reclaims vast intellectual capital, potentially increasing grant submission volume and success rates.

Deployment Risks Specific to This Size Band

Deploying AI across an organization of 5,000-10,000 employees, especially one embedded within a larger hospital system, presents unique challenges. Data Integration and Silos are paramount; research data is often fragmented across different hospitals, labs, and legacy systems, requiring substantial investment in unified data platforms before AI models can be trained effectively. Change Management at this scale is complex, requiring buy-in from hundreds of independent principal investigators and clinical teams accustomed to traditional workflows. Regulatory and Compliance Hurdles are intensified; all AI tools handling patient data must navigate stringent HIPAA, IRB, and ethical review processes, which can slow deployment. Finally, Talent Retention is a risk, as the competition for AI and data science talent in Boston is fierce, necessitating strong partnerships with local universities and clear career pathways to build and retain an internal AI team.